



(51) International Patent Classification:

C07D 209/44 (2006.01) **C07D 487/14** (2006.01)
A61K 31/4035 (2006.01) **C07D 413/14** (2006.01)
A61K 31/454 (2006.01) **C07D 405/14** (2006.01)
C07D 407/10 (2006.01) **A61K 31/416** (2006.01)
C07D 401/06 (2006.01) **C07D 409/14** (2006.01)
C07D 407/06 (2006.01) **A61K 31/4245** (2006.01)
A61K 31/4439 (2006.01) **A61K 31/423** (2006.01)
A61K 31/4178 (2006.01) **A61K 31/4155** (2006.01)
A61K 31/5377 (2006.01) **A61K 31/69** (2006.01)
A61K 31/55 (2006.01) **A61K 31/427** (2006.01)
A61K 31/541 (2006.01) **A61K 31/422** (2006.01)
C07D 417/06 (2006.01) **A61K 31/506** (2006.01)
C07D 413/06 (2006.01) **C07D 403/12** (2006.01)
A61K 31/496 (2006.01) **C07D 471/04** (2006.01)
A61K 31/5386 (2006.01) **A61K 31/436** (2006.01)
C07D 403/06 (2006.01) **A61K 31/538** (2006.01)
A61K 31/553 (2006.01) **C07D 413/10** (2006.01)
A61K 31/4985 (2006.01) **A61P 31/18** (2006.01)

(30) Priority Data:

62/021,844 8 July 2014 (08.07.2014) US
 62/064,615 16 October 2014 (16.10.2014) US
 62/134,616 18 March 2015 (18.03.2015) US

(71) Applicant: **VIIV HEALTHCARE UK LIMITED**
[GB/GB]; 980 Great West Road, Brentford Middlesex
TW8 9GS (GB).

(72) Inventors: **JOHNS, Brian, Alvin**; c/o GlaxoSmithKline, Global Patents, Five Moore Drive, Research Triangle Park, North Carolina 27709 (US). **VELTHUISEN, Emile, Johann**; c/o GlaxoSmithKline, Global Patents, Five Moore Drive, Research Triangle Park, North Carolina 27709 (US). **WEATHERHEAD, Jason, Gordan**; c/o GlaxoSmithKline, Global Patents, Five Moore Drive, Research Triangle Park, North Carolina 27709 (US). **SUWANDI, Lita**; c/o GlaxoSmithKline, Global Patents, Five More Drive, Research Triangle Park, North Carolina 27709 (US). **TEMELKOFF, David**; c/o GlaxoSmithKline, Global Patents, Five Moore Drive, Research Triangle Park, North Carolina 27709 (US).

(21) International Application Number:

PCT/IB2015/055095

(22) International Filing Date:

6 July 2015 (06.07.2015)

(25) Filing Language:

English

(26) Publication Language:


English

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,

[Continued on next page]

(54) Title: ISOINDOLINE DERIVATIVES FOR USE IN THE TREATMENT OF A VIRAL INFECTION

(57) Abstract: Compounds of Formula I are disclosed and methods of treating viral infections with compositions comprising such compounds (Formula I)



Formula I



KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE,

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))